Core Biogenesis Raises $10.5M To Accelerate Plant-Based Bioproduction
Amount Raised
$10.5 Million
StrasbourgBiotechnologyHealth CareDescription
Core Biogenesis, an emerging biotechnology company with a novel plant-based bioproduction platform, recently completed a $10.5M Series A funding round. The funds will be used to build out an industrial scale facility dedicated to producing growth factors and cytokines for the burgeoning cell therapy market and cellular agriculture industry, and to hire additional scientific and technical staff to support the expansion. The funding round was led by XAnge, a Paris-based science and technology venture capital firm. Other investors include Blue Horizon Ventures, a Zurich-based venture capital firm with a focus on protein alternatives and food tech, and Thia Ventures, an investor at the crossroads of biotechnology, nutrition and health, with offices in Geneva, Luxembourg, Belgium and Singapore.